NCT06242834

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, enrolled Phase 2 Last updated 1 April 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in B-Cell Non-Hodgkin Lymphoma in 32 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 September 2024

Primary endpoint
24 April 2027

24 November 2028

Quick facts

Lead sponsor	Northwestern University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	30 September 2024
Primary completion	24 April 2027
Estimated completion	24 November 2028
Sites	2 locations across United States

Drugs / interventions tested

• Biospecimen Collection — full drug profile →
• Computed Tomography
• Echocardiography
• Pembrolizumab (pembrolizumab) — full drug profile →
• Positron Emission Tomography
• Tazemetostat (tazemetostat) — full drug profile →

Conditions studied

• B-Cell Non-Hodgkin Lymphoma — all drugs for B-Cell Non-Hodgkin Lymphoma →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and tazemetostat may work better to treat patients who have received ASCT or CAR-T cell therapy for aggressive non hodgkins lymphoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Epigenetic drugs in cancer therapy.
   Suraweera A, O'Byrne KJ, Richard DJ. · · 2025 · cited 50× · PMID 40011240 · DOI 10.1007/s10555-025-10253-7
2. Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
   Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
3. Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.
   Xue E, Adeyelu T, Krause H, Elliott A, et al · · 2026 · cited 1× · PMID 41221671 · DOI 10.1002/hed.70076
4. The role of <i>EZH2</i> dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy.
   Candelaria M. · · 2026 · PMID 42211521 · DOI 10.3389/fonc.2026.1843273
5. Targeting epigenetic regulators to boost T cell immunotherapy against cancer.
   Xiao T, Zhang YE. · · 2026 · PMID 41634788 · DOI 10.1186/s13578-026-01533-y